Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.
Press releases published on May 2, 2025
GE Aerospace Unions Rally For Fair Contract & Workers Rights As Trade War Disruption Looms
EIN Presswire
·
May 2, 2025
IUE-CWA Workers Across the U.S. Stand in Solidarity with Aerospace Workers Worldwide in May Day Celebration LYNN, MA, UNITED STATES, May 2, 2025 /EINPresswire.com/ -- On May Day 2025, IUE-CWA Local 201 hosted delegations of GE Aerospace workers from …
SATENA Honored as Leader in Enhancing Accessibility in Colombian Air Travel – Colombia by Global Brand Frontier Awards
EIN Presswire
·
May 2, 2025
SATENA wins “Leader in Enhancing Accessibility in Colombian Air Travel – 2024” for boosting regional connectivity and inclusive air transport services. BOSTON, MA, UNITED STATES, May 2, 2025 /EINPresswire.com/ -- SATENA, Colombia’s national airline, …
Jessica Murphy of Tarlow, Breed, Hart & Rodgers, P.C. Named 'Go To Lawyer' for Construction
EIN Presswire
·
May 2, 2025
Recognized by Massachusetts Lawyers Weekly for her exceptional work and numerous contributions to field of construction law. BOSTON, MA, UNITED STATES, May 2, 2025 /EINPresswire.com/ -- Tarlow, Breed, Hart …
BarberTime Cinco de Mayo Event Empowers Latino Barbers and Stylists to Take Charge of Their Financial Future
EIN Presswire
·
May 2, 2025
BarberTime Media Network and Brookline Bank partner to help Latino barbers and stylists in Boston gain financial tools and build generational wealth. BOSTON, MA, UNITED STATES, May 2, 2025 /EINPresswire.com/ -- The BarberTime Media Network, in …
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 2, 2025
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 2, 2025
WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, …
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 2, 2025
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, …
Great Elm Group, Inc. Schedules Fiscal 2025 Third Quarter Conference Call and Webcast
GlobeNewswire
·
May 2, 2025
PALM BEACH GARDENS, Fla., May 02, 2025 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“Great Elm”) (NASDAQ: GEG), today announced plans to release financial results for the fiscal quarter ended March 31, 2025, after the close of market trading on Wednesday, …
Cell-Based Assays: The Future of Biomedical Breakthroughs
GlobeNewswire
·
May 2, 2025
Boston, May 02, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the demand for Cell-Based Assays: Technologies and Global Markets is estimated to increase from $35.3 billion in 2024 to $56.3 billion by 2029, at a compound annual …
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 2, 2025
On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for …
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
GlobeNewswire
·
May 2, 2025
CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the …